Company / Operating Income
Zenas BioPharma, Inc. Operating Income History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$383.1M
FY2025
5-year range
-$383.1M / -$37.1M
FY2023-FY2025
Trend
-931.2%
vs FY2024
Sector context
#175 of 204
Health Care
What the data says
Operating Income changed -931% YoY in FY2025, a notable deviation from the 2-year average annual change of -466%.
Based on SEC 10-K filings.
-$383M in FY2025.
Declined from -$37M to -$383M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 204This company -$383.1M Sector average $107.7M
▼
-455.6% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 931.2% year-over-year.
- Ranks #175 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$383.1M | -931.2% |
| FY2024 | -$37.1M | +0.0% |
| FY2023 | -$37.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026